Studies related to Matrix Metalloproteinase 3 and L-Carnitine

L-Carnitine supplementation ameliorates serum tumor necrosis factor-alpha and matrix metalloproteinase-3 in knee osteoarthritis women
Effect Decrease
Values Serum (pg/ml). Mean and SD. Placebo: before 26.5 ± 9.5, after 27.7 ± 11.0 . Carnitine: before 29.5 ± 13.3, after 24.5 ± 12.7.
Trial Design Randomized trial
Trial Length 1-6 months
Number of Subjects 72
Sex Female
Age Range 30-44, 45-64
Body Types Obese, Overweight
Notes for this study:
In a randomized, double-blind, placebo-controlled trial, 72 participants with mild to moderate knee osteoarthritis took 750 mg of l-carnitine or placebo daily for 2 months. There was a statistically significant reduction in serum TNF-a and reduction in matrix metalloproteinase-3. There was also a greater improvement in the Physicians Global Assessment Of The Severity of Knee Osteoarthritis.